Early predictions about manufacturability, expression, and process development challenges based on a candidate’s sequence and structure can allow for modifications that increase the likelihood of a successful first-in-human (FIH) manufacturing campaign.

In silico and in vitro design and optimization serve as valuable tools in these assessments by not only identifying but also mitigating risks, ultimately optimizing early expression and material supply processes to improve developability of the candidate molecule.


  • Rebecca Michael, PhD., Head of Cell and Molecular Biology, Lonza Early Development Services


By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center